Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy

Masaki Shiota; Dai Takamatsu; Yoshiyuki Matsui; Akira Yokomizo; Shuichi Morizane; Ryoichi Saito; Makito Miyake; Masakazu Tsutsumi; Yoshiyuki Yamamoto; Kojiro Tashiro; Ryotaro Tomida; Shintaro Narita; Kohei Edamura; Takahiro Yamaguchi; Kohei Hashimoto; Masashi Kato; Takashi Kasahara; Takayuki Yoshino; Shusuke Akamatsu; Tomoyuki Kaneko; Akihiro Matsukawa; Ryuji Matsumoto; Akira Joraku; Toshihiro Saito; Takuma Kato; Manabu Kato; Hideki Enokida; Shinichi Sakamoto; Naoki Terada; Hidenori Kanno; Naotaka Nishiyama; Takahiro Kimura; Hiroshi Kitamura; Masatoshi Eto

doi:10.1245/s10434-024-14999-2

Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy

Masaki Shiota^*, Dai Takamatsu, Yoshiyuki Matsui, Akira Yokomizo, Shuichi Morizane, Ryoichi Saito, Makito Miyake, Masakazu Tsutsumi, Yoshiyuki Yamamoto, Kojiro Tashiro, Ryotaro Tomida, Shintaro Narita, Kohei Edamura, Takahiro Yamaguchi, Kohei Hashimoto, Masashi Kato, Takashi Kasahara, Takayuki Yoshino, Shusuke Akamatsu, Tomoyuki KanekoAkihiro Matsukawa, Ryuji Matsumoto, Akira Joraku, Toshihiro Saito, Takuma Kato, Manabu Kato, Hideki Enokida, Shinichi Sakamoto, Naoki Terada, Hidenori Kanno, Naotaka Nishiyama, Takahiro Kimura, Hiroshi Kitamura, Masatoshi Eto

^*Corresponding author for this work

Urology

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Background: This study aimed to create a prognostic model to predict disease recurrence among patients with lymph node involvement but no prostate-specific antigen (PSA) persistence and to explore its clinical utility. Methods: The study analyzed patients with lymph node involvement after pelvic lymph node dissection with radical prostatectomy in whom no PSA persistence was observed between 2006 and 2019 at 33 institutions. Prognostic factors for recurrence-free survival (RFS) were analyzed by the Cox proportional hazards model. Results: Among 231 patients, 127 experienced disease recurrence. The factors prognostic for RFS were PSA level at diagnosis (≥ 20 vs. < 20 ng/mL: hazard ratio [HR], 1.66; 95% confidence interval [CI], 1.09–2.52; P = 0.017), International Society of Urological Pathology grade group at radical prostatectomy (RP) specimen (group ≥ 4 vs. ≤ 3: HR, 1.63; 95% CI 1.12–2.37; P = 0.010), pathologic T-stage (pT3b/4 vs. pT2/3a: HR, 1.70; 95% CI 1.20–2.42; P = 0.0031), and surgical margin status (positive vs. negative: HR, 1.60; 95% CI 1.13–2.28; P = 0.0086). The prognostic model using four parameters were associated with RFS and metastasis-free survival. Conclusion: The prognostic model in combination with postoperative PSA value and number of lymph nodes is clinically useful for discussing treatment choice with patients.

Original language	English
Pages (from-to)	3872-3879
Number of pages	8
Journal	Annals of Surgical Oncology
Volume	31
Issue number	6
DOIs	https://doi.org/10.1245/s10434-024-14999-2
State	Published - 2024/06

Keywords

Biochemical recurrence
Lymph node involvement
PSA persistence
Predictive factor
Radical prostatectomy

ASJC Scopus subject areas

Surgery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1245/s10434-024-14999-2

Cite this

Shiota, M., Takamatsu, D., Matsui, Y., Yokomizo, A., Morizane, S., Saito, R., Miyake, M., Tsutsumi, M., Yamamoto, Y., Tashiro, K., Tomida, R., Narita, S., Edamura, K., Yamaguchi, T., Hashimoto, K., Kato, M., Kasahara, T., Yoshino, T., Akamatsu, S., ... Eto, M. (2024). Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy. Annals of Surgical Oncology, 31(6), 3872-3879. https://doi.org/10.1245/s10434-024-14999-2

@article{99acc69cefd044318f928cc2684ea3a2,

title = "Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy",

abstract = "Background: This study aimed to create a prognostic model to predict disease recurrence among patients with lymph node involvement but no prostate-specific antigen (PSA) persistence and to explore its clinical utility. Methods: The study analyzed patients with lymph node involvement after pelvic lymph node dissection with radical prostatectomy in whom no PSA persistence was observed between 2006 and 2019 at 33 institutions. Prognostic factors for recurrence-free survival (RFS) were analyzed by the Cox proportional hazards model. Results: Among 231 patients, 127 experienced disease recurrence. The factors prognostic for RFS were PSA level at diagnosis (≥ 20 vs. < 20 ng/mL: hazard ratio [HR], 1.66; 95% confidence interval [CI], 1.09–2.52; P = 0.017), International Society of Urological Pathology grade group at radical prostatectomy (RP) specimen (group ≥ 4 vs. ≤ 3: HR, 1.63; 95% CI 1.12–2.37; P = 0.010), pathologic T-stage (pT3b/4 vs. pT2/3a: HR, 1.70; 95% CI 1.20–2.42; P = 0.0031), and surgical margin status (positive vs. negative: HR, 1.60; 95% CI 1.13–2.28; P = 0.0086). The prognostic model using four parameters were associated with RFS and metastasis-free survival. Conclusion: The prognostic model in combination with postoperative PSA value and number of lymph nodes is clinically useful for discussing treatment choice with patients.",

keywords = "Biochemical recurrence, Lymph node involvement, PSA persistence, Predictive factor, Radical prostatectomy",

author = "Masaki Shiota and Dai Takamatsu and Yoshiyuki Matsui and Akira Yokomizo and Shuichi Morizane and Ryoichi Saito and Makito Miyake and Masakazu Tsutsumi and Yoshiyuki Yamamoto and Kojiro Tashiro and Ryotaro Tomida and Shintaro Narita and Kohei Edamura and Takahiro Yamaguchi and Kohei Hashimoto and Masashi Kato and Takashi Kasahara and Takayuki Yoshino and Shusuke Akamatsu and Tomoyuki Kaneko and Akihiro Matsukawa and Ryuji Matsumoto and Akira Joraku and Toshihiro Saito and Takuma Kato and Manabu Kato and Hideki Enokida and Shinichi Sakamoto and Naoki Terada and Hidenori Kanno and Naotaka Nishiyama and Takahiro Kimura and Hiroshi Kitamura and Masatoshi Eto",

note = "Publisher Copyright: {\textcopyright} Society of Surgical Oncology 2024.",

year = "2024",

month = jun,

doi = "10.1245/s10434-024-14999-2",

language = "英語",

volume = "31",

pages = "3872--3879",

journal = "Annals of Surgical Oncology",

issn = "1068-9265",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "6",

}

Shiota, M, Takamatsu, D, Matsui, Y, Yokomizo, A, Morizane, S, Saito, R, Miyake, M, Tsutsumi, M, Yamamoto, Y, Tashiro, K, Tomida, R, Narita, S, Edamura, K, Yamaguchi, T, Hashimoto, K, Kato, M, Kasahara, T, Yoshino, T, Akamatsu, S, Kaneko, T, Matsukawa, A, Matsumoto, R, Joraku, A, Saito, T, Kato, T, Kato, M, Enokida, H, Sakamoto, S, Terada, N, Kanno, H, Nishiyama, N, Kimura, T, Kitamura, H & Eto, M 2024, 'Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy', Annals of Surgical Oncology, vol. 31, no. 6, pp. 3872-3879. https://doi.org/10.1245/s10434-024-14999-2

TY - JOUR

T1 - Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy

AU - Shiota, Masaki

AU - Takamatsu, Dai

AU - Matsui, Yoshiyuki

AU - Yokomizo, Akira

AU - Morizane, Shuichi

AU - Saito, Ryoichi

AU - Miyake, Makito

AU - Tsutsumi, Masakazu

AU - Yamamoto, Yoshiyuki

AU - Tashiro, Kojiro

AU - Tomida, Ryotaro

AU - Narita, Shintaro

AU - Edamura, Kohei

AU - Yamaguchi, Takahiro

AU - Hashimoto, Kohei

AU - Kato, Masashi

AU - Kasahara, Takashi

AU - Yoshino, Takayuki

AU - Akamatsu, Shusuke

AU - Kaneko, Tomoyuki

AU - Matsukawa, Akihiro

AU - Matsumoto, Ryuji

AU - Joraku, Akira

AU - Saito, Toshihiro

AU - Kato, Takuma

AU - Kato, Manabu

AU - Enokida, Hideki

AU - Sakamoto, Shinichi

AU - Terada, Naoki

AU - Kanno, Hidenori

AU - Nishiyama, Naotaka

AU - Kimura, Takahiro

AU - Kitamura, Hiroshi

AU - Eto, Masatoshi

PY - 2024/6

Y1 - 2024/6

N2 - Background: This study aimed to create a prognostic model to predict disease recurrence among patients with lymph node involvement but no prostate-specific antigen (PSA) persistence and to explore its clinical utility. Methods: The study analyzed patients with lymph node involvement after pelvic lymph node dissection with radical prostatectomy in whom no PSA persistence was observed between 2006 and 2019 at 33 institutions. Prognostic factors for recurrence-free survival (RFS) were analyzed by the Cox proportional hazards model. Results: Among 231 patients, 127 experienced disease recurrence. The factors prognostic for RFS were PSA level at diagnosis (≥ 20 vs. < 20 ng/mL: hazard ratio [HR], 1.66; 95% confidence interval [CI], 1.09–2.52; P = 0.017), International Society of Urological Pathology grade group at radical prostatectomy (RP) specimen (group ≥ 4 vs. ≤ 3: HR, 1.63; 95% CI 1.12–2.37; P = 0.010), pathologic T-stage (pT3b/4 vs. pT2/3a: HR, 1.70; 95% CI 1.20–2.42; P = 0.0031), and surgical margin status (positive vs. negative: HR, 1.60; 95% CI 1.13–2.28; P = 0.0086). The prognostic model using four parameters were associated with RFS and metastasis-free survival. Conclusion: The prognostic model in combination with postoperative PSA value and number of lymph nodes is clinically useful for discussing treatment choice with patients.

AB - Background: This study aimed to create a prognostic model to predict disease recurrence among patients with lymph node involvement but no prostate-specific antigen (PSA) persistence and to explore its clinical utility. Methods: The study analyzed patients with lymph node involvement after pelvic lymph node dissection with radical prostatectomy in whom no PSA persistence was observed between 2006 and 2019 at 33 institutions. Prognostic factors for recurrence-free survival (RFS) were analyzed by the Cox proportional hazards model. Results: Among 231 patients, 127 experienced disease recurrence. The factors prognostic for RFS were PSA level at diagnosis (≥ 20 vs. < 20 ng/mL: hazard ratio [HR], 1.66; 95% confidence interval [CI], 1.09–2.52; P = 0.017), International Society of Urological Pathology grade group at radical prostatectomy (RP) specimen (group ≥ 4 vs. ≤ 3: HR, 1.63; 95% CI 1.12–2.37; P = 0.010), pathologic T-stage (pT3b/4 vs. pT2/3a: HR, 1.70; 95% CI 1.20–2.42; P = 0.0031), and surgical margin status (positive vs. negative: HR, 1.60; 95% CI 1.13–2.28; P = 0.0086). The prognostic model using four parameters were associated with RFS and metastasis-free survival. Conclusion: The prognostic model in combination with postoperative PSA value and number of lymph nodes is clinically useful for discussing treatment choice with patients.

KW - Biochemical recurrence

KW - Lymph node involvement

KW - PSA persistence

KW - Predictive factor

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=85185132763&partnerID=8YFLogxK

U2 - 10.1245/s10434-024-14999-2

DO - 10.1245/s10434-024-14999-2

M3 - 学術論文

C2 - 38353798

AN - SCOPUS:85185132763

SN - 1068-9265

VL - 31

SP - 3872

EP - 3879

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

IS - 6

ER -

Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this